Unlocking High-Quality NGS Data from Challenging Clinical Samples

Extracting meaningful multi-omic insights from DNA and RNA sequencing data generated from challenging clinical specimens remains a common obstacle in biomarker-driven research and clinical trials. In this webinar, the featured speakers will discuss how nucleic acid yield and quality influence NGS success, review practical considerations when working with challenging clinical specimens and explain why FFPE remains one of the most important and challenging sample types for integrated genomic and transcriptomic analysis.

Through real-world examples, attendees will gain insights into approaches to maximise data generation, improve assay success rates and support confident decision-making in precision medicine programs

What You Will Learn

Attendees will gain insight into:

• How sample quality affects NGS Data generation and assay success
• Practical considerations when working with challenging clinical specimens
• Why FFPE remains one of the most important and most challenging sample types for NGS
• Approaches to maximize data generation from challenging clinical specimens

Dr. Martin McLaughlin, Senior Genomic Services Manager, Almac Diagnostic Services

Dr. Martin McLaughlin holds a BSc in Biochemistry and a PhD in Molecular Biology from Queen’s University Belfast.

He spent more than a decade at The Institute of Cancer Research, London, where his research focused on DNA damage response inhibitors, radiotherapy and cancer immunotherapies. His work has been published in leading scientific journals, including Clinical Cancer Research, OncoImmunology and Nature Reviews Cancer.

Martin joined Almac Diagnostic Services in 2021. In his role, he oversees biomarker discovery projects for global biopharma clients, with expertise in next-generation sequencing and difficult clinical specimens.